CA3048434A1 - Synthetic guide molecules, compositions and methods relating thereto - Google Patents
Synthetic guide molecules, compositions and methods relating thereto Download PDFInfo
- Publication number
- CA3048434A1 CA3048434A1 CA3048434A CA3048434A CA3048434A1 CA 3048434 A1 CA3048434 A1 CA 3048434A1 CA 3048434 A CA3048434 A CA 3048434A CA 3048434 A CA3048434 A CA 3048434A CA 3048434 A1 CA3048434 A1 CA 3048434A1
- Authority
- CA
- Canada
- Prior art keywords
- linkage
- independently
- integer
- guide molecule
- inclusive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C[C@]1(*)O[C@@](C)(COC)C(I)=C1OCNC(N*OC[C@@]1(C)O[C@@](*)C(*)=C1*)=O Chemical compound C[C@]1(*)O[C@@](C)(COC)C(I)=C1OCNC(N*OC[C@@]1(C)O[C@@](*)C(*)=C1*)=O 0.000 description 38
- AHLCKVKSFVNEPW-UHFFFAOYSA-N CCN1N(NNNN2N3N4N5N(N6N7N8N6N6N8N(N)N6C)N7N5N4N3N2N2)N2N1CC Chemical compound CCN1N(NNNN2N3N4N5N(N6N7N8N6N6N8N(N)N6C)N7N5N4N3N2N2)N2N1CC AHLCKVKSFVNEPW-UHFFFAOYSA-N 0.000 description 1
- RFVXVEIIOGAYRV-UHFFFAOYSA-N CCN1N(NNNN2N3N4N5N(N6N7N8N6N6N8N(N)N6NC)N7N5N4N3N2N2)N2N1CC Chemical compound CCN1N(NNNN2N3N4N5N(N6N7N8N6N6N8N(N)N6NC)N7N5N4N3N2N2)N2N1CC RFVXVEIIOGAYRV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662441046P | 2016-12-30 | 2016-12-30 | |
| US62/441,046 | 2016-12-30 | ||
| US201762492001P | 2017-04-28 | 2017-04-28 | |
| US62/492,001 | 2017-04-28 | ||
| PCT/US2017/069019 WO2018126176A1 (en) | 2016-12-30 | 2017-12-29 | Synthetic guide molecules, compositions and methods relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3048434A1 true CA3048434A1 (en) | 2018-07-05 |
Family
ID=61187807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3048434A Pending CA3048434A1 (en) | 2016-12-30 | 2017-12-29 | Synthetic guide molecules, compositions and methods relating thereto |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230111575A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3565895A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7167029B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102758180B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN110249052B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017388753A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3048434A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX420023B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018126176A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3957735A1 (en) | 2014-03-05 | 2022-02-23 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
| US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
| EP3116997B1 (en) | 2014-03-10 | 2019-05-15 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) |
| US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
| WO2015148863A2 (en) | 2014-03-26 | 2015-10-01 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
| EP3540061A1 (en) | 2014-04-02 | 2019-09-18 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating primary open angle glaucoma |
| EP4019975A1 (en) | 2015-04-24 | 2022-06-29 | Editas Medicine, Inc. | Evaluation of cas9 molecule/guide rna molecule complexes |
| US11512311B2 (en) | 2016-03-25 | 2022-11-29 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency |
| WO2017220751A1 (en) | 2016-06-22 | 2017-12-28 | Proqr Therapeutics Ii B.V. | Single-stranded rna-editing oligonucleotides |
| US11566263B2 (en) | 2016-08-02 | 2023-01-31 | Editas Medicine, Inc. | Compositions and methods for treating CEP290 associated disease |
| DK3507366T3 (da) | 2016-09-01 | 2020-11-02 | Proqr Therapeutics Ii Bv | Kemisk modificeret, enkeltstrengede rna-modificerende oligonukleotider |
| EP3571300A1 (en) | 2017-01-19 | 2019-11-27 | ProQR Therapeutics II B.V. | Oligonucleotide complexes for use in rna editing |
| CN110662554A (zh) | 2017-02-28 | 2020-01-07 | Vor生物制药股份有限公司 | 用于抑制谱系特异性蛋白质的组合物和方法 |
| WO2018170184A1 (en) | 2017-03-14 | 2018-09-20 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| EP3615672A1 (en) | 2017-04-28 | 2020-03-04 | Editas Medicine, Inc. | Methods and systems for analyzing guide rna molecules |
| EP3622070A2 (en) | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
| US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| US20190076814A1 (en) | 2017-09-11 | 2019-03-14 | Synthego Corporation | Biopolymer synthesis system and method |
| SG11202008956XA (en) | 2018-03-14 | 2020-10-29 | Editas Medicine Inc | Systems and methods for the treatment of hemoglobinopathies |
| WO2019222545A1 (en) | 2018-05-16 | 2019-11-21 | Synthego Corporation | Methods and systems for guide rna design and use |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| EP3823633A4 (en) | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO |
| AU2019333104A1 (en) | 2018-08-28 | 2021-03-25 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| GB201901873D0 (en) * | 2019-02-11 | 2019-04-03 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for nucleic acid editing |
| WO2020237217A1 (en) | 2019-05-23 | 2020-11-26 | Vor Biopharma, Inc | Compositions and methods for cd33 modification |
| KR20220047380A (ko) | 2019-08-28 | 2022-04-15 | 보르 바이오파마 인크. | Cll1 변형을 위한 조성물 및 방법 |
| CN114787352A (zh) | 2019-08-28 | 2022-07-22 | Vor生物制药股份有限公司 | 用于cd123修饰的组合物和方法 |
| WO2022047165A1 (en) | 2020-08-28 | 2022-03-03 | Vor Biopharma Inc. | Compositions and methods for cd123 modification |
| US20240110189A1 (en) | 2020-08-28 | 2024-04-04 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| US20230398219A1 (en) | 2020-09-14 | 2023-12-14 | Vor Biopharma Inc. | Compositions and methods for cd38 modification |
| JP2023541458A (ja) | 2020-09-14 | 2023-10-02 | ブイオーアール バイオファーマ インコーポレーテッド | Ｃｄ５修飾のための化合物および方法 |
| EP4214318A1 (en) | 2020-09-18 | 2023-07-26 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| WO2022067240A1 (en) | 2020-09-28 | 2022-03-31 | Vor Biopharma, Inc. | Compositions and methods for cd6 modification |
| US20230364146A1 (en) | 2020-09-30 | 2023-11-16 | Vor Biopharma Inc. | Compositions and methods for cd30 gene modification |
| JP2023548111A (ja) | 2020-10-27 | 2023-11-15 | ブイオーアール バイオファーマ インコーポレーテッド | 造血悪性腫瘍を治療するための組成物および方法 |
| WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
| US20230414755A1 (en) | 2020-11-13 | 2023-12-28 | Vor Biopharma Inc. | Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors |
| KR20230126707A (ko) | 2020-12-31 | 2023-08-30 | 보르 바이오파마 인크. | Cd34 유전자 변형을 위한 조성물 및 방법 |
| WO2022217086A1 (en) | 2021-04-09 | 2022-10-13 | Vor Biopharma Inc. | Photocleavable guide rnas and methods of use thereof |
| WO2023283585A2 (en) | 2021-07-06 | 2023-01-12 | Vor Biopharma Inc. | Inhibitor oligonucleotides and methods of use thereof |
| WO2023015182A1 (en) | 2021-08-02 | 2023-02-09 | Vor Biopharma Inc. | Compositions and methods for gene modification |
| WO2023049926A2 (en) | 2021-09-27 | 2023-03-30 | Vor Biopharma Inc. | Fusion polypeptides for genetic editing and methods of use thereof |
| JP2024543369A (ja) | 2021-11-09 | 2024-11-21 | ブイオーアール バイオファーマ インコーポレーテッド | Ｅｍｒ２修飾のための化合物及び方法 |
| US20250179531A1 (en) | 2022-02-25 | 2025-06-05 | Vor Biopharma Inc. | Compositions and methods for homology-directed repair gene modification |
| US20250295695A1 (en) | 2022-04-04 | 2025-09-25 | Vor Biopharma Inc. | Compositions and methods for mediating epitope engineering |
| WO2024015925A2 (en) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
| EP4623081A2 (en) * | 2022-11-23 | 2025-10-01 | Prime Medicine, Inc. | Split synthesis of long rnas |
| WO2024168312A1 (en) | 2023-02-09 | 2024-08-15 | Vor Biopharma Inc. | Methods for treating hematopoietic malignancy |
| US20250006305A1 (en) * | 2023-06-29 | 2025-01-02 | Synthego Corporation | Methods and systems for automated fraction selection in nucleic acid manufacturing |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
| WO2025194138A1 (en) | 2024-03-14 | 2025-09-18 | Tessera Therapeutics, Inc. | St1cas9 compositions and methods for modulating a genome |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013055690A1 (en) * | 2011-10-10 | 2013-04-18 | Kmt Waterjet Systems Inc. | Gasketless high pressure connection |
| CN106459995B (zh) * | 2013-11-07 | 2020-02-21 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| EP3116997B1 (en) | 2014-03-10 | 2019-05-15 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) |
| WO2015148863A2 (en) * | 2014-03-26 | 2015-10-01 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
| EP3204513A2 (en) * | 2014-10-09 | 2017-08-16 | Life Technologies Corporation | Crispr oligonucleotides and gene editing |
| WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| US10059940B2 (en) * | 2015-01-27 | 2018-08-28 | Minghong Zhong | Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents |
| CA2981715A1 (en) * | 2015-04-06 | 2016-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
| EP4019975A1 (en) * | 2015-04-24 | 2022-06-29 | Editas Medicine, Inc. | Evaluation of cas9 molecule/guide rna molecule complexes |
| EP3763814A1 (en) | 2015-05-08 | 2021-01-13 | The Children's Medical Center Corporation | Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction |
| EP3294880A4 (en) * | 2015-05-15 | 2018-12-26 | Dharmacon, Inc. | Synthetic single guide rna for cas9-mediated gene editing |
| EP3409776A4 (en) * | 2016-01-30 | 2019-12-25 | Bonac Corporation | ARTIFICIAL SINGLE GUIDE RNA AND THEIR USE |
| EP3443088B1 (en) | 2016-04-13 | 2024-09-18 | Editas Medicine, Inc. | Grna fusion molecules, gene editing systems, and methods of use thereof |
-
2017
- 2017-12-29 KR KR1020237043357A patent/KR102758180B1/ko active Active
- 2017-12-29 CN CN201780085248.4A patent/CN110249052B/zh active Active
- 2017-12-29 AU AU2017388753A patent/AU2017388753A1/en not_active Abandoned
- 2017-12-29 CA CA3048434A patent/CA3048434A1/en active Pending
- 2017-12-29 KR KR1020197022278A patent/KR102618864B1/ko active Active
- 2017-12-29 WO PCT/US2017/069019 patent/WO2018126176A1/en not_active Ceased
- 2017-12-29 CN CN202410342599.0A patent/CN118345072A/zh active Pending
- 2017-12-29 MX MX2019007750A patent/MX420023B/es unknown
- 2017-12-29 US US16/474,198 patent/US20230111575A1/en active Pending
- 2017-12-29 EP EP17840468.7A patent/EP3565895A1/en active Pending
- 2017-12-29 JP JP2019535879A patent/JP7167029B2/ja active Active
-
2022
- 2022-09-26 JP JP2022152461A patent/JP7610559B2/ja active Active
-
2024
- 2024-07-30 AU AU2024205204A patent/AU2024205204A1/en active Pending
- 2024-11-08 JP JP2024195755A patent/JP2025016776A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR102618864B1 (ko) | 2024-01-02 |
| CN118345072A (zh) | 2024-07-16 |
| MX2019007750A (es) | 2019-10-15 |
| US20230111575A1 (en) | 2023-04-13 |
| JP7167029B2 (ja) | 2022-11-08 |
| CN110249052B (zh) | 2024-04-12 |
| AU2017388753A1 (en) | 2019-07-11 |
| KR20190110554A (ko) | 2019-09-30 |
| JP2022173349A (ja) | 2022-11-18 |
| JP2020503049A (ja) | 2020-01-30 |
| MX420023B (es) | 2025-01-14 |
| CN110249052A (zh) | 2019-09-17 |
| EP3565895A1 (en) | 2019-11-13 |
| JP7610559B2 (ja) | 2025-01-08 |
| KR20230175330A (ko) | 2023-12-29 |
| KR102758180B1 (ko) | 2025-01-23 |
| AU2024205204A1 (en) | 2024-09-05 |
| WO2018126176A1 (en) | 2018-07-05 |
| JP2025016776A (ja) | 2025-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7610559B2 (ja) | 合成ガイド分子、それに関連する組成物および方法 | |
| US11692205B2 (en) | Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA | |
| US11597924B2 (en) | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use | |
| US20190300872A1 (en) | Improved Methods of Genome Editing with and without Programmable Nucleases | |
| CA3085338A1 (en) | Cpf1-related methods and compositions for gene editing | |
| CA3089843A1 (en) | Systems and methods for modulating chromosomal rearrangements | |
| CA2969464A1 (en) | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides | |
| US12338436B2 (en) | Synthetic guide molecules, compositions and methods relating thereto | |
| NZ795956A (en) | Synthetic guide molecules, compositions and methods relating thereto | |
| NZ754735A (en) | Synthetic guide molecules, compositions and methods relating thereto | |
| NZ795268A (en) | Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220922 |
|
| EEER | Examination request |
Effective date: 20220922 |
|
| EEER | Examination request |
Effective date: 20220922 |
|
| EEER | Examination request |
Effective date: 20220922 |